Literature DB >> 1183141

Absolute bioavailability in man of N-acetylprocainamide determined by a novel stable isotope method.

J M Strong, J S Dutcher, W K Lee, A J Atkinson.   

Abstract

Absorption of a single oral dose of N-acetylprocainamide (NAPA) was studied in 3 normal subjects. Approximately 85% of the oral dose was absorbed and peak plasma NAPA concentrations were reached in 45 to 90 min. In 2 subjects, NAPA was absorbed at a fast initial rate, then more slowly, prolonging the apparent elimination phase half-life. Absolute bioavailability was determined by a new stable isotope method that entailed intravenous injection of NAPA 13C at the same time that an unlabeled NAPA capsule was given orally. Plasma levels and urine excretion of both compounds were determined by mass fragmentography. Bioavailability was assessed by deconvoluting the plasma level vs time curves resulting from intravenous and oral drug administration, and also by comparing the relative percentage of NAPA and NAPA-13C excreted unchanged in the 24 hr after simultaneous administration.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1183141     DOI: 10.1002/cpt1975185part1613

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  19 in total

1.  Bioavailability estimation by semisimultaneous drug administration: a Monte Carlo simulation study.

Authors:  M O Karlsson; U Bredberg
Journal:  J Pharmacokinet Biopharm       Date:  1990-04

2.  Concurrent intravenous administration of a labeled tracer to determine the oral bioavailability of a drug exhibiting Michaelis-Menten metabolism.

Authors:  G M Rubin; J A Waschek; S M Pond; D J Effeney; T N Tozer
Journal:  J Pharmacokinet Biopharm       Date:  1987-12

Review 3.  Effect of active drug metabolites on plasma level-response correlations.

Authors:  A J Atkinson; J M Strong
Journal:  J Pharmacokinet Biopharm       Date:  1977-04

4.  The assessment of bioavailability in the presence of nonlinear elimination.

Authors:  S D Hall; C B McAllister; G R Wilkinson
Journal:  J Pharmacokinet Biopharm       Date:  1988-06

5.  Inter- and intra-subject variability of metoprolol kinetics after intravenous administration.

Authors:  J Richard; J M Cardot; J Godbillon
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1994 Apr-Jun       Impact factor: 2.441

Review 6.  New antiarrhythmic drugs: their place in therapy.

Authors:  D L Keefe; R E Kates; D C Harrison
Journal:  Drugs       Date:  1981-11       Impact factor: 9.546

Review 7.  Pharmacologically active metabolites of drugs and other foreign compounds. Clinical, pharmacological, therapeutic and toxicological considerations.

Authors:  D E Drayer
Journal:  Drugs       Date:  1982-12       Impact factor: 9.546

Review 8.  Application of stable labelled drugs in clinical pharmacokinetic investigations.

Authors:  M Eichelbaum; G E von Unruh; A Somogyi
Journal:  Clin Pharmacokinet       Date:  1982 Nov-Dec       Impact factor: 6.447

Review 9.  Pharmacokinetic studies in pregnancy.

Authors:  Michael J Avram
Journal:  Semin Perinatol       Date:  2020-01-27       Impact factor: 3.300

10.  Comparative antiarrhythmic efficacy of intravenous N-acetylprocainamide and procainamide.

Authors:  C Sonnhag; E Karlsson
Journal:  Eur J Clin Pharmacol       Date:  1979-06-12       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.